Medizinonline Medizinonline
  • News
    • News
    • Market & Medicine
  • Patients
    • Disease patterns
    • Diagnostics
    • Therapy
  • Partner Content
    • Dermatology
      • Atopic dermatitis and psoriasis news
      • Dermatology News
    • Diabetes
      • Dia-Month Club – Type 2 Diabetes
      • Diabetes in Motion
      • Diabetes Podcasts
    • Gastroenterology
      • IBD matters
      • Forum Gastroenterology
      • Ozanimod: ulcerative colitis
      • Reflux Update
    • Immunology
      • Primary immunodeficiency – exchange of experience
    • Vaccinate
      • Herpes zoster
    • Infektiologie
    • Neurology
      • EXPERT ULTRASONIC: Introduction to ultrasound-guided injection
      • MS News
      • MS Therapy in Transition
    • Oncology
      • Swiss Oncology in motion
    • Orthopedics
      • Osteoporosis in motion
    • Phytotherapie
    • Practice Management
      • Aargau Cantonal Bank
      • Claraspital
    • Psychiatry
      • Geriatric Psychiatry
    • Rheumatology
  • Departments
    • Allergology and clinical immunology
    • General Internal Medicine
    • Anesthesiology
    • Angiology
    • Surgery
    • Dermatology and venereology
    • Endocrinology and Diabetology
    • Nutrition
    • Gastroenterology and Hepatology
    • Genetics
    • Geriatrics
    • Gynecology
    • Hematology
    • Infectiology
    • Cardiology
    • Nephrology
    • Neurology
    • Emergency and intensive care medicine
    • Nuclear Medicine
    • Oncology
    • Ophthalmology
    • ORL
    • Orthopedics
    • Pediatrics
    • Pharmacology and toxicology
    • Pharmaceutical medicine
    • Phlebology
    • Physical medicine and rehabilitation
    • Pneumology
    • Prevention and health care
    • Psychiatry and psychotherapy
    • Radiology
    • Forensic Medicine
    • Rheumatology
    • Sports Medicine
    • Traumatology and trauma surgery
    • Tropical and travel medicine
    • Urology
    • Dentistry
  • CME & Congresses
    • CME continuing education
    • Congress Reports
    • Congress calendar
  • Practice
    • Noctimed
    • Practice Management
    • Jobs
    • Interviews
  • Log In
  • Register
  • My account
  • Contact
  • English
    • Deutsch
    • Français
    • Italiano
    • Português
    • Español
  • Publications
  • Contact
  • Deutsch
  • English
  • Français
  • Italiano
  • Português
  • Español
Subscribe
Medizinonline Medizinonline
Medizinonline Medizinonline
  • News
    • News
    • Market & Medicine
  • Patienten
    • Krankheitsbilder
    • Diagnostik
    • Therapie
  • Partner Content
    • Dermatology
      • Atopic dermatitis and psoriasis news
      • Dermatology News
    • Diabetes
      • Dia-Month Club – Type 2 Diabetes
      • Diabetes in Motion
      • Diabetes Podcasts
    • Gastroenterology
      • IBD matters
      • Forum Gastroenterology
      • Ozanimod: ulcerative colitis
      • Reflux Update
    • Immunology
      • Primary immunodeficiency – exchange of experience
    • Vaccinate
      • Herpes zoster
    • Infektiologie
    • Neurology
      • EXPERT ULTRASONIC: Introduction to ultrasound-guided injection
      • MS News
      • MS Therapy in Transition
    • Oncology
      • Swiss Oncology in motion
    • Orthopedics
      • Osteoporosis in motion
    • Phytotherapie
    • Practice Management
      • Aargau Cantonal Bank
      • Claraspital
    • Psychiatry
      • Geriatric Psychiatry
    • Rheumatology
  • Departments
    • Fachbereiche 1-13
      • Allergology and clinical immunology
      • General Internal Medicine
      • Anesthesiology
      • Angiology
      • Surgery
      • Dermatology and venereology
      • Endocrinology and Diabetology
      • Nutrition
      • Gastroenterology and Hepatology
      • Genetics
      • Geriatrics
      • Gynecology
      • Hematology
    • Fachbereiche 14-26
      • Infectiology
      • Cardiology
      • Nephrology
      • Neurology
      • Emergency and intensive care medicine
      • Nuclear Medicine
      • Oncology
      • Ophthalmology
      • ORL
      • Orthopedics
      • Pediatrics
      • Pharmacology and toxicology
      • Pharmaceutical medicine
    • Fachbereiche 26-38
      • Phlebology
      • Physical medicine and rehabilitation
      • Phytotherapy
      • Pneumology
      • Prevention and health care
      • Psychiatry and psychotherapy
      • Radiology
      • Forensic Medicine
      • Rheumatology
      • Sports Medicine
      • Traumatology and trauma surgery
      • Tropical and travel medicine
      • Urology
      • Dentistry
  • CME & Congresses
    • CME continuing education
    • Congress Reports
    • Congress calendar
  • Practice
    • Noctimed
    • Practice Management
    • Jobs
    • Interviews
Login

Sie haben noch keinen Account? Registrieren

  • Hematologic neoplasms

Differentiated diagnostics for effective results

    • Congress Reports
    • Hematology
    • Oncology
    • RX
    • Studies
  • 1 minute read

Differentiated diagnostic options are designed to enable therapy that is tailored to individual needs. However, in hematologic neoplasms, established treatment options are also effective.

For the treatment of rare indolent lymphoma, R-Benda (rituximab and bendamustine), DRC (dexamethasone, rituximab, and cyclophosphamide), and BDR (bortezomib, dexamethasone, and rituximab) are primarily used. These three regimens were compared in terms of their effectiveness. Patients with WM who were evaluated at Mayo Clinic between 2000 and 2018 and were on one of three primary therapies were included.

There was a clear advantage for the combination of rituximab and bendamustine (R-Benda). The ORR was 95%, whereas BDR was 81% and DRC was 76%. Complete remissions of as much as 10% could only be demonstrated for the R-Benda regimen. Very good partial remission (VGPR) was 21% and partial remission was 62% (Fig. 1). However, with regard to overall survival, there were no differences between the individual therapeutic approaches.

The retrospective cohort demonstrated that first-line R-Benda therapy was superior to DRC or BDR in terms of response, time to next therapy, and progression-free survival, independent of a MYD88L265P mutation. In terms of their toxicity profile, the three regimens were comparable. Only under BDR did grade 3 neurotoxicity occur in 13%.

 

Further reading:

  • Abeykoon JP, et al: Outcomes with rituximab plus bendamustine (R-Benda), dexamethasone, rituximab, caclophosphamide (DRC), and bortezomib, dexamethasone, rituximab (BDR) as primary therapy in patients with Waldenstrom macroglobulinemia (WM). ASCO Annual Meeting 2019, Abstract 7509.

InFo ONCOLOGY & HEMATOLOGY 2019;(2-3): 30 (published 6/17/19, ahead of print).

Publikation
  • InFo ONKOLOGIE & HÄMATOLOGIE
Related Topics
  • first-line therapy
  • Hematologic neoplasms
  • Waldenström macroglobulinemia
Previous Article
  • Parkinson's disease

What to do when fluctuations occur?

  • Education
  • Neurology
  • RX
View Post
Next Article
  • Cardiooncology

Deciphering cardiotoxicity using relevant biomarkers.

  • Cardiology
  • Education
  • Oncology
  • RX
View Post
You May Also Like
View Post
  • 4 min
  • Journal Club: Drinking restriction in heart failure

First large-scale study found no differences

    • Cardiology
    • Education
    • General Internal Medicine
    • Nutrition
    • Prevention and health care
    • RX
    • Studies
View Post
  • 3 min
  • Therapy adherence and patient selection

Injection fatigue in relapsing-remitting multiple sclerosis

    • Education
    • Neurology
    • RX
    • Studies
View Post
  • 5 min
  • Deep vein thrombosis

Outpatient or inpatient treatment?

    • Angiology
    • Cardiology
    • Congress Reports
    • General Internal Medicine
    • Phlebology
    • RX
    • Studies
View Post
  • 5 min
  • Sarcoidosis, echinococcosis & Co.

Suspected symptoms and differential diagnoses

    • Cardiology
    • Cases
    • Congress Reports
    • Pneumology
    • RX
View Post
  • 12 min
  • Cancer prevention

Constant dripping – alcohol and cancer

    • CME continuing education
    • General Internal Medicine
    • Oncology
    • Pharmacology and toxicology
    • Prevention and health care
    • Psychiatry and psychotherapy
    • RX
    • Studies
View Post
  • 7 min
  • Steatotic liver disease

GLP-1RA in MASH – what’s new?

    • Congress Reports
    • Endocrinology and Diabetology
    • Gastroenterology and Hepatology
    • General Internal Medicine
    • Pharmacology and toxicology
    • RX
    • Studies
View Post
  • 6 min
  • Chronic pruritus: “Tour d'horizon”

Focus on new anti-inflammatory therapeutic approaches

    • Allergology and clinical immunology
    • Congress Reports
    • Dermatology and venereology
    • Pharmacology and toxicology
    • RX
    • Studies
View Post
  • 5 min
  • Multiple sclerosis

Unexpected side effects when switching from natalizumab to a biosimilar

    • Education
    • Neurology
    • Pharmacology and toxicology
    • RX
    • Studies
Top Partner Content
  • Forum Gastroenterology

    Zum Thema
  • Herpes zoster

    Zum Thema
  • Dermatology News

    Zum Thema
Top CME content
  • 1
    Constant dripping – alcohol and cancer
  • 2
    Hurdles to pain treatment for autistic patients
  • 3
    Current and future approaches in the treatment of amyotrophic lateral sclerosis (ALS)
  • 4
    Treatment of comorbidities in older people
  • 5
    New nomenclature for non-alcoholic fatty liver disease

Newsletter

Sign up and stay up to date

Subscribe
Medizinonline
  • Contact
  • General terms and conditions
  • Imprint

Input your search keywords and press Enter.